



# MAPK11 (p38 $\beta$ ) is a major determinant of cellular radiosensitivity by controlling ionizing radiation-associated senescence: An in vitro study

D.M. Fernández-Aroca<sup>a,1,2,\*</sup>, N. García-Flores<sup>a,1</sup>, S. Frost<sup>b</sup>, J. Jiménez-Suárez<sup>a</sup>,  
A. Rodríguez-González<sup>b</sup>, P. Fernández-Aroca<sup>a</sup>, S. Sabater<sup>c</sup>, I. Andrés<sup>c</sup>, C. Garnés-García<sup>a</sup>,  
B. Belandía<sup>d</sup>, F.J. Cimas<sup>a,e</sup>, D. Villar<sup>b</sup>, M.J. Ruiz-Hidalgo<sup>a,e,2</sup>, R. Sánchez-Prieto<sup>a,d,2,\*</sup>

<sup>a</sup> Laboratorio de Oncología Molecular, Unidad de Medicina Molecular, Centro Regional de Investigaciones Biomédicas, Universidad de Castilla-La Mancha. Unidad Asociada de Biomedicina UCLM, Unidad asociada al CSIC, Albacete, España

<sup>b</sup> Centre for Genomics and Child Health, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom

<sup>c</sup> Servicio de Oncología Radioterápica, Complejo Hospitalario Universitario de Albacete, Albacete, España

<sup>d</sup> Departamento de Biología del Cáncer, Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM), Madrid, España. Unidad Asociada de Biomedicina UCLM, Unidad asociada al CSIC, España

<sup>e</sup> Área de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de Castilla-La Mancha, Albacete, España

## ARTICLE INFO

### Keywords:

Ionizing radiation  
Radiosensitization  
Senescence  
MAPK11  
P38 $\beta$

## ABSTRACT

**Background and purpose:** MAPKs are among the most relevant signalling pathways involved in coordinating cell responses to different stimuli. This group includes p38MAPKs, constituted by 4 different proteins with a high sequence homology: MAPK14 (p38 $\alpha$ ), MAPK11 (p38 $\beta$ ), MAPK12 (p38 $\gamma$ ) and MAPK13 (p38 $\delta$ ). Despite their high similarity, each member shows unique expression patterns and even exclusive functions. Thus, analysing protein-specific functions of MAPK members is necessary to unequivocally uncover the roles of this signalling pathway. Here, we investigate the possible role of MAPK11 in the cell response to ionizing radiation (IR).

**Materials and methods:** We developed MAPK11/14 knockdown through shRNA and CRISPR interference gene perturbation approaches and analysed the downstream effects on cell responses to ionizing radiation in A549, HCT-116 and MCF-7 cancer cell lines. Specifically, we assessed IR toxicity by clonogenic assays; DNA damage response activity by immunocytochemistry; apoptosis and cell cycle by flow cytometry (Annexin V and propidium iodide, respectively); DNA repair by comet assay; and senescence induction by both X-Gal staining and gene expression of senescence-associated genes by RT-qPCR.

**Results:** Our findings demonstrate a critical role of MAPK11 in the cellular response to IR by controlling the associated senescent phenotype, and without observable effects on DNA damage response, apoptosis, cell cycle or DNA damage repair.

**Conclusion:** Our results highlight MAPK11 as a novel mediator of the cellular response to ionizing radiation through the control exerted onto IR-associated senescence.

## 1. Introduction

Radiotherapy, applied to around 50% of cancer patients, has become a cornerstone in cancer therapy [1], being especially relevant in some types of tumours such as breast, colorectal or lung [2]. It is therefore

essential to uncover the molecular and biological processes triggered by ionising radiation (IR) which could improve the effectiveness of treatments. Consequently, the search of mechanisms responsible for sensitisation and resistance to radiotherapy, both *de novo* and acquired, has been a long-standing issue in radiobiology [3–6]. Several signalling

**Abbreviations:** DDR, DNA damage response; DSB, Double strand break; gRNA, Guide RNA; IR, Ionizing radiation; MAPK, Mitogen Activated Protein Kinase; RT-qPCR, Quantitative real-time PCR; S.D., Standard deviation; SF, Surviving fraction; shRNA, short hairpin RNA.

\* Corresponding authors at: Laboratorio de Oncología Molecular, Facultad de Medicina de Albacete, Universidad de Castilla La Mancha (D.M. Fernández Aroca); Instituto de Investigaciones Biomédicas de Madrid. Lab 1.5.2 (R. Sánchez Prieto).

E-mail addresses: [d.fernandezaroca@qmul.ac.uk](mailto:d.fernandezaroca@qmul.ac.uk) (D.M. Fernández-Aroca), [rsprieto@iib.uam.es](mailto:rsprieto@iib.uam.es) (R. Sánchez-Prieto).

<sup>1</sup> Both authors have contributed equally to this work.

<sup>2</sup> These senior authors have contributed equally to this work.

<https://doi.org/10.1016/j.ctro.2023.100649>

Received 6 March 2023; Received in revised form 30 May 2023; Accepted 30 May 2023

Available online 2 June 2023

2405-6308/© 2023 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

pathways [7], biological processes [8,9], genetic alterations [10,11], and even epigenetic modifications [12] have been related to the cellular response to IR. However, we still do not have a complete picture of the molecular elements involved in this biological response that could contribute to improve and personalise radiotherapy. Within p38MAPK family, four proteins can be found: MAPK14, MAPK11, MAPK12 and MAPK13. With the term p38MAPK we will refer to all four proteins. Despite these members sharing high sequence homology [13], each of them shows not just different tissue expression patterns [14,15] but also specific functions in different biological processes [16,17] and different implications in cancer [18]. Furthermore, even opposite roles for each member have been described [19] (e.g. in activating AP-1-dependent transcription in breast cancer cell lines [20] or in pancreatic cancer [15,21]). Most of the current evidence linking p38MAPK and cancer focuses onto MAPK14, due to its ubiquitous and abundant expression [22]. However, a growing body of data support a key role in cancer for other members of the family, for instance MAPK12 and MAPK13 [23,24]. Indeed, recent evidence indicates important roles for MAPK11 in cancer and its therapy (for a review see [25]). Nonetheless, p38MAPK signalling pathway has been linked with the response to DNA damage and, specifically, to IR. TAO kinases are able to activate p38MAPK through ATM/ATR pathways in response to IR [26,27], emerging as regulators of p38-mediated response to DNA damage [26]. It is also remarkable that p38MAPK has been found to be critical in biological/biochemical processes triggered by IR, such as IR-induced apoptosis [28] or AKT activation [29]. Among the p38MAPK members, which have been specifically proposed as mediators of cell response to IR, MAPK14 has been implicated in a plethora of effects ranging from autophagy [30] up to cell cycle control [31], whereas the rest of members (MAPK11, 12 and 13) have been barely studied in response to IR [32–34]. In addition, it is noteworthy that the vast majority of publications assessing p38MAPK roles are based on pharmacological approaches including those related to IR (e.g. [35–42]), which at best allow to distinguish MAPK11/14 from MAPK12/13, but not addressing protein-specific functions for each p38MAPK family member.

Against this background, we aimed to clarify the specific role of MAPK11 in the cellular response to radiotherapy in different experimental models, including colon, lung, and breast cancer cell lines by using genetic approaches to fully exploit the potential role of this particular MAPK in radiotherapy.

## 2. Materials and methods

### 2.1. Cell lines and plasmids

A549 (Lung cancer), HCT-116 (Colon cancer) MCF-7 (Breast cancer) and HEK293T cells have been cultured as previously described [43]. Cells were maintained in 5% CO<sub>2</sub> and 37 °C; and grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 1% glutamine and 1% Penicillin/Streptomycin. All cell culture reagents were provided by Lonza.

Plasmids used for shRNA interference (Sigma-Aldrich) were as follows: Human pLKO.1-puro-shRNAMAPK14 (Sigma SHCLNG-NM\_001315; TRCN000000511), Human pLKO.1-puro-shRNAMAPK11 (Sigma SHCLNG-NM\_002751; (TRCN0000199694), and pLKO.1-puro empty vector (Sigma SHC001). For CRISPR interference (CRISPRi) were as follows: TRE-dCas9-KRAB-IRES-GFP (Addgene #85556) [44], and pU6-sgRNA-puro-BFP (Addgene #60955) [45].

### 2.2. Transfections and infections

Lentiviral production and cell infection were performed as previously described [46,47].

### 2.3. Inducible CRISPR interference (CRISPRi)

A549 cells were infected with lentiviruses containing TRE-dCas9-KRAB-IRES-GFP [48], treated for 4 days with 1 µg/ml doxycycline and then GFP-positive cells were sorted by flow cytometry. Next, dCas9-expressing cells were infected with pU6 plasmids harbouring non-target control (NTC) or sgMAPK11 gRNAs and selected with 1 µg/ml puromycin for 3 days. To achieve full dCas9 expression, cells were treated with 1 µg/ml doxycycline 5 days prior to cell seeding and maintained over the course of the experiments.

gRNAs (Supplementary Table S1) were designed with CHOPCHOP [49], purchased from IDT, and cloned into pU6-sgRNA-puro-BFP as previously described [50].

### 2.4. Western blotting

Protein quantification and western blotting were performed as previously described [33]. Antibodies used are summarized in Supplementary Table S2. Images show a representative experiment out of three with similar results.

### 2.5. Immunocytochemistry

Cells were grown onto SPL cell culture slides (Labclininc) 24 h prior to irradiation. After treatment cells were fixed, permeabilized and incubated with the indicated antibodies (Supplementary Table S2) as previously described [51]. Positive immuno-fluorescence was detected using a Zeiss Apotome fluorescence microscope and processed using Zen 2009 Light Edition program (Zeiss). Foci quantification was performed with CellProfiler (Broad) [52]. Images show a representative cell from a minimum of 100 quantified (5 fields per sample captured). Data shown are the average of, at least, three independent experiments.

### 2.6. RNA isolation, reverse transcription and Real-time Quantitative PCR

Total RNA was obtained as previously described [53]. cDNA synthesis was performed with RevertAid First Strand cDNA synthesis Kit (Thermo Scientific) following manufacturer's protocol in an iCycler thermal cycler (Biorad). Real time PCR was performed with Fast SYBR Green Master kit (Thermo Scientific) in a 7500 Fast Real-Time PCR instrument (Applied Biosystems). PCR conditions were as previously described [53]. Primers for all target sequences were designed by using NCBI BLAST software and purchased from Merck as DNA oligos. Primer sequences can be found in Supplementary Table S1. Data shown are the average of, at least, three independent experiments performed in triplicate.

### 2.7. Irradiation and clonogenic assays

Cells were irradiated by the technical staff of the Radiotherapy Unit at University General Hospital of Albacete, in a Clinac Low Energy 600C linear electron accelerator from Varian (Palo Alto, California, USA) at a dose rate of 600 cGy/min in a radiation field of 40x40 cm. Clonogenic assays were performed and valuated as previously described [53,54]. Plates were photographed and colonies were counted with the ImageJ plugin "Cell counter". Colonies with <5 mm diameter were discarded. Values were referred to unirradiated controls, set at 1. SF2Gy was calculated by applying a linear-quadratic model [55]. Data shown are the average of, at least, three independent experiments performed in triplicated cultures.

### 2.8 β-galactosidase activity

Six days after irradiation, cells were washed in PBS, fixed for 5 min (room temperature) in 12% formalin, washed twice for 5 min, and incubated for 16 h at 37 °C (no CO<sub>2</sub>) with fresh SA-β-Gal staining [56].

Images were acquired at 10x using a Zeiss Apotome. Images show a representative field out of 5 acquired per sample (minimum of 100 cells quantified per condition). Data shown are the average of three independent experiments.

## 2.9. Flow cytometry

For cell cycle analysis,  $10^5$  cells were seeded in 6 cm plates 24 h prior to irradiation and cell cycle was analysed as previously described at indicated times [43]. For apoptosis detection,  $10^5$  cells were seeded in 6 cm plates, 24 h later cells were treated with IR and, after 48 h, apoptosis was detected with Annexin V-FITC (Immunostep) following manufacturer's instructions.

Samples were processed in a MACSQuant Analyzer 10 (Miltenyi Biotec). Data were analysed by using FlowingSoftware (University of Turku). Data shown are the average of, at least, three independent experiments performed.

## 2.10. Comet assay

DNA fragmentation and repair was measured with the alkaline comet assay [57]. Images were acquired at 10x magnification using a Zeiss Apotome fluorescence microscope and analysed with the plugin Open-Comet [58] (ImageJ) to measure tail moment (DNA% in tail \* tail length). Data shown are the average of three independent experiments.

## 2.11. Cell proliferation measurements

For cell proliferation measurements,  $10^4$  cells/well were seeded in 24-well plates and proliferation was analysed 1, 2 and 3 days later by an MTT-based assay as previously described [33]. Data shown are the average of three independent experiments performed in triplicated cultures.


## 2.12. Statistical analysis

Data are presented as mean  $\pm$  standard deviation (S.D). Statistical significance was evaluated by Student's *t*-test (immunocytochemistry, apoptosis,  $\beta$ -galactosidase activity, RT-qPCR, and comet assays) or ANOVA (clonogenic and cell cycle assays) using GraphPad Prism v9.0 software. The statistical significance of differences is indicated in figures by asterisks as follows: ns = non significant, \**p* < 0.05, \*\**p* < 0.01 and \*\*\**p* < 0.001.

For Kaplan-Meier curves, analysis was performed in cBioPortal [59] by using curated TCGA Pan-Cancer series. The differences between survival curves were examined using the log-rank test. Patients were segregated depending on *MAPK11* mRNA levels.

## 3. Results

Given the implication of p38MAPK in the cellular response to IR, we first aimed to interrogate the specific role of MAPK11 and MAPK14, the two highly and ubiquitously expressed members of p38MAPK, across A549 (lung), HCT-116 (colon) and MCF-7 (breast) cancer cell lines.



**Fig. 1.** Genetic abrogation of MAPK11 promotes radiosensitivity in A549, HCT-116 and MCF-7 cell lines. A) A549 cells were infected with lentiviruses carrying scramble control (Scramble), shRNA for MAPK11 (shMAPK11) or MAPK14 (shMAPK14). Genetic interference was evaluated by western blot using tubulin as a loading control. B) Clonogenic assays for A549 cells infected with Scramble, shMAPK11 or shMAPK14 and exposed to the indicated doses of X rays. Surviving fraction was normalized to respective unirradiated controls. Curves were fitted using lineal-quadratic model. Bars mean standard deviation (S.D). C) A549 Scramble, shMAPK11 and shMAPK14 surviving fraction at 2 Gy (SF2Gy)  $\pm$  S.D. calculated by lineal-quadratic model. D) Same as in A) for HCT-116 cells. E) Same as in B) for HCT-116 cells. F) Same as in C) for HCT-116 cells. G) Same as in A) for MCF-7 cells. H) Same as in B) for MCF-7 cells. I) Same as in C) for MCF-7 cells. Statistical significance of differences was evaluated by ANOVA followed by Bonferroni's multiple comparison test. \*\**p* < 0.01 and \*\*\**p* < 0.001.

After achieving an effective *MAPK14* or *MAPK11* knockdown by shRNA (Fig. 1A, D, G and Sup. Fig. S1), we analysed clonogenicity after IR exposure by 15-days clonogenic assays. We did not observe a significant effect upon *MAPK14* abrogation in any of the cell lines tested, however, knockdown of *MAPK11* led to a significant reduction in cell survival after IR exposure (Fig. 1B, E and H) in all three cell lines, but did not affect neither proliferation nor clonogenicity in the absence of radiation (Sup. Fig. S2). Indeed, SF2Gy showed a marked and specific decrease upon MAPK11 ablation (Fig. 1C, F and I), suggesting a potential role for this MAPK in radiobiology.


Since the activity of DNA Damage Response (DDR) is one of the most important cell pathways activated in response to IR, we next investigated whether MAPK11 plays any role in this signalling pathway by choosing as experimental model the A549 cell line. To this end, we analysed activation of key molecules in the cellular response to DNA damage, such as ATM and the homologous-recombination repair mediator BRCA1. These experiments showed no differences in the number of pATM/pBRCA1 foci per nuclei in cells with reduced MAPK11 expression compared to control cells (Scramble) (Fig. 2A). This result was also confirmed by comet assay, in which no differences in DNA repair capacity were found (Fig. 2B). Furthermore, we confirmed these results in MCF-7 and HCT-116 cell lines (Sup. Fig. S3), thus concluding that MAPK11 does not play a direct role in mediating DDR activity.

Next, we studied MAPK11 effects in terms of IR-associated cell cycle blockage and apoptosis induction, as these are other two relevant, early cellular responses to DNA damage. We did not observe MAPK11 to have a determinant role onto G2/M accumulation 24 h after treatment with radiotherapy in A549 cells (Fig. 3A). Interestingly, we observed a slight but non-significant premature release from G2/M blockage in shMAPK11 cells 48 h after IR. Regarding IR-induced apoptosis, we did not find significant differences in induction of apoptosis (Anexin V+


cells) 48 h after IR exposure in A549 (Fig. 3B), HCT-116 or MCF-7 cell lines (Sup. Fig. S3). Therefore, the collective evidence from these experiments discards a direct role of MAPK11 in the early cellular response to IR, at least within the first 48 h after induction of DNA damage.

In light of the lack of effect in early responses, we reasoned out that the radiosensitivity we observed in 15-days clonogenic assays (Fig. 1) could be triggered by a later cellular response. In order to study other biological consequences of IR, we investigated induction of cellular senescence, which is known to onset several days after irradiation [60]. To this end, we assessed IR-induced  $\beta$ -Gal activity 6 days after IR in cells infected with Scramble or shMAPK11, as a well-established indicator of senescence. As shown in Fig. 4A, A549 cells harbouring shRNA targeting MAPK11 undergo enhanced induction of senescence-like phenotypes compared to control cells. In addition, we confirmed these results by analysing gene expression of well-established senescence markers such as IL-1 $\beta$ , p21, IL-6 and IL-8 [61], observing a significant induction of all of them after MAPK11 knockdown, compared to Scramble cells (Fig. 4B). In sum, our results indicate that the lack of MAPK11 could promote a marked increase in cellular senescence secondary to irradiation.

To verify our observations based on shRNA, we developed a complementary epigenetic perturbation approach based on doxycycline (dox)-inducible CRISPR interference. After achieving an effective knockdown (Fig. 5A, Sup 4A), we performed clonogenic assays with A549 cells harbouring a dox-inducible dCas9-KRAB and a non-target control gRNA (NTC) or a gRNA targeting *MAPK11* promoter (sgMAPK11). In line with shRNA data, CRISPRi knockdown of MAPK11 was able to sensitize A549 cell line to IR (Fig. 5B) showing a lower SF2Gy (NTC = 76.05 $\pm$ 8.6; sgMAPK11 = 43.65 $\pm$ 3.5). Moreover, both biochemical and biological effects of CRISPRi knockdown were similar to those obtained with shRNA: no effect was observed on DNA damage repair, p-ATM foci formation and apoptosis induction (Sup. Fig. S4),



**Fig. 2. MAPK11 does not modulate DDR activity and DNA repair in response to ionising radiation.** A) *Upper panels:* A549 cells harbouring Scramble or shMAPK11 were plated onto cell culture slides 24 h prior to irradiation (10 Gy) and 4 h later cells were fixed and processed for immunocytochemistry against phospho-ATM (Ser1981) or phospho-BRCA1 (Ser1524). Images show a representative cell out of a minimum of 100 analysed. *Lower panels:* Quantification of phospho-ATM or phospho-BRCA1 foci number per nuclei in three independent experiments. Bars mean standard deviation (S.D.). Statistical significance of differences was evaluated by *t*-test. ns = non significant. B) *Left panel:* Comet assay analysis of A549 Scramble and shMAPK11 cells. After irradiation (10 Gy) DNA damage was evaluated at the indicated times. Images show a representative cell out of a minimum of 100 analysed. *Right panel:* Histogram showing comet tail moment normalized to Scramble unirradiated controls. Bars mean standard deviation (S.D.). Statistical significance of differences was evaluated by ANOVA followed by Bonferroni's multiple comparison test. ns = non significant.



**Fig. 3.** MAPK11 does not deregulate cell cycle and apoptosis after irradiation in A549 cell line. A) *Upper panel*: Image of a representative cell cycle profile in A549 Scramble and shMAPK11 cells irradiated at 10 Gy. Cell cycle was evaluated by flow cytometry at the indicated times after IR. *Lower panel*: Histogram showing the average of three independent experiments representing the percentage of population in the different phases of the cell cycle. Bars mean S.D. Statistical significance of differences was evaluated by ANOVA followed by Bonferroni's multiple comparison test. B) *Upper panel*: Graphical representation of apoptosis induction in A549 Scramble and shMAPK11 cells 48 h after irradiation (10 Gy) by staining with Annexin V-FITC/Propidium Iodide for assay by flow cytometry. *Lower panel*: Histogram showing the average of three independent experiments to evaluate the percentage of apoptotic A549 Scramble or shMAPK11 cells 48 h after IR (10 Gy). Bars mean S.D. Statistical significance of differences was evaluated by *t*-test. ns = non significant.

while, as expected, senescence induction was increased in cells upon MAPK11 CRISPRi knockdown, in terms of both  $\beta$ -Gal staining and expression of senescence-related genes (Fig. 5C and D). Collectively, these results confirm those obtained with shRNA interference, and strongly suggest an important role for MAPK11 in mediating the cellular response to IR.


To evaluate the generality of our observations, we assessed  $\beta$ -Gal activity and induction of IL-1 $\beta$ , IL-6, IL-8 and p21 in response to IR in HCT-116 and MCF-7 cell lines with and without MAPK11 expression. In both experimental models, we observed an enhancement of  $\beta$ -Gal activity and gene expression profile associated to IR-dependent senescence (Fig. 6A – D), thus confirming that MAPK11 could be involved in the induction of senescence in response to IR. Finally, to evaluate the clinical implications of our findings, we performed an *in silico* analysis by using the cBioPortal platform, which stores information from the TCGA database including patient data upon radiotherapy treatment for almost all tumour types. The percentage of MAPK11 mutations detected in the TCGA Pan-Cancer series (10967 samples) is extremely low (Sup. Fig. S5A), with no statistical implications on overall or specific survival, as well as on disease-free survival. Next, we analysed MAPK11 expression levels in the TCGA series showing differential behaviour depending on tumour type (e.g., clear cell renal cell carcinoma or pancreatic adenocarcinoma, see Sup. Fig. S5B and C). However, the limited number of patients treated with radiotherapy for most tumour types restricted our analyses to invasive breast cancer (1084 patients of whom 549 received radiotherapy). Interestingly, in this entire series, high or low MAPK11 levels did not indicate any difference in survival (Sup. Fig. S5D), however, analysis of patients who were irradiated showed that a high MAPK11 level correlated with a worse response (Fig. 6E). Therefore, this *in silico* analysis points to a clear relationship between MAPK11 expression levels and clinical outcome, in terms of overall survival of patients undergoing radiotherapy treatment, thus supporting

a key role for this MAPK in radiobiology and radiotherapy.


#### 4. Discussion

IR triggers a broad, complex, and highly regulated cellular response involving a wide variety of signalling pathways including the super-family of MAPKs. Despite p38MAPK, mainly MAPK14, has been deeply studied in relation to IR, no connection has been established, to the best of our knowledge, between MAPK11 and the cellular response to IR. In the present work we have observed how MAPK11 abrogation drives a marked increase in cellular sensitivity to IR, regardless of the genetic perturbation approach applied and the cancer cell line studied, in line with previous findings from our lab [33]. Interestingly, no differences in DNA damage response, cell cycle arrest and apoptosis, all of them early responses to IR [62], were detected in association with those observed in clonogenic assays. Conversely, radiosensitization associated with MAPK11 abrogation could be explained by a promotion of IR-induced senescence, a critical late-onset cellular effect associated to IR [60], establishing MAPK11 as a new key player in the cellular response to IR.

The key finding of our work is the observation of a clear enhancement of IR-associated senescence in the absence of MAPK11, with no apparent role for MAPK14. Although it has been reported that activation of p38MAPK, mainly MAPK14, can promote senescence associated to IR [63,64], this effect seems to be not applicable to several experimental systems in which senescence is promoted after inhibition of p38MAPK [65,66]. Moreover, all these previous works are based on the use of the SB203580 inhibitor [67], which does not allow to distinguish between MAPK11 and 14, and in most, if not all the cases, MAPK14 was assumed to be the key mediator. Albeit no previous studies have focused on the role of MAPK11 in radiobiology, several papers have shown a role for MAPK11 in the response to oxidative stress, controlling the cell fate by blocking processes like apoptosis, senescence or autophagy in different




**Fig. 4. MAPK11 genetic interference enhances cell senescence in response to ionizing radiation.** A) Upper panel: A549 Scramble or shMAPK11 cells were irradiated (10 Gy) and 5 days later  $\beta$ -Gal activity was detected by X-gal staining. A representative image is shown. Scale bars represent 10  $\mu$ m. Lower panel: Histogram showing the average of, at least, three independent experiments representing the percentage of positive senescent cells. Bars mean S.D. Statistical significance of differences was evaluated by *t*-test. \*\*\**p* < 0.001. B) Gene expression of indicated senescence-associated genes was evaluated 5 days after IR (10 Gy) in A549 Scramble or shMAPK11 cells by RT-qPCR using GAPDH as an endogenous control. Data were referred to unirradiated Scramble cells. Bars mean S.D. Statistical significance of differences was evaluated by *t*-test. \*\**p* < 0.01 and \*\*\**p* < 0.001.



**Fig. 5. Epigenetic perturbation of MAPK11 by CRISPRi confirms its role in cell response to ionizing radiation.** A) A549 cells expressing dCas9 were infected with lentiviruses carrying non-target-control (NTC) or MAPK11-targeted sgRNAs (sgMAPK11). Interference was evaluated by western blot using tubulin as a loading control. B) Clonogenic assays for A549 NTC and sgMAPK11 cell exposed to the indicated doses of X rays. Bars mean standard deviation (S.D.). Statistical significance of differences was evaluated by ANOVA followed by Bonferroni's multiple comparison test. \**p* < 0.05, \*\*\**p* < 0.001. C) Histograms show the average of three independent experiments representing the percentage of positive senescent cells evaluated by X-Gal staining 5 days after IR (10 Gy). Bars indicate S.D. Statistical significance of differences was evaluated by *t*-test. \*\*\**p* < 0.001. D) Gene expression of indicated senescence-associated genes was evaluated 5 days after IR (10 Gy) in A549 NTC or sgMAPK11 cells by RT-qPCR using GAPDH as an endogenous control. Data were referred to unirradiated NTC cells. Bars mean S.D. Statistical significance of differences was evaluated by *t*-test. \*\**p* < 0.01 and \*\*\**p* < 0.001.

experimental models such as brain [68], muscle [69] and cardiomyocytes [70]. Furthermore, it has been reported how abrogation of MAPK11 is required for the activity of tumor suppressor genes and some miRNAs, supporting an oncogenic and pro-survival role for this MAPK [71,72]. In addition, other possibilities should be considered. For example, the histone deacetylase HDAC3, which has been recently

proposed as a key regulator of Senescence Associated Secretory Phenotype [73], is known to interact with MAPK11 [74], suppressing the transcriptional activity of ATF-2. Interestingly, ATF-2 is known to promote survival and efficient DNA repair after IR exposure [75] that could render radioresistance [76,77]. Furthermore, p38MAPK has been proposed to block senescence in response to IR by the control exerted onto



**Fig. 6.** Genetic interference of MAPK11 increases induction of senescence in response to ionizing radiation in HCT-116 and MCF-7 cell lines. A) HCT-116 Scramble and shMAPK11 cells were irradiated (10 Gy) and 5 days later senescence was evaluated by X-Gal staining. Histogram shows the average of three independent experiments representing the percentage of positive senescent cells. Bars mean standard deviation (S.D.). B) Gene expression of indicated senescence-associated genes was evaluated 5 days after IR (10 Gy) in HCT-116 Scramble and shMAPK11 cells by RT-qPCR using GAPDH as endogenous control. Data were referred to unirradiated Scramble cells. Bars mean S.D. C) Same as in A) for MCF-7 cells. D) Same as in B) for MCF-7 cells. In A-D statistical significance of differences was evaluated by *t*-test. \*\* $p < 0.01$  and \*\*\* $p < 0.001$ . E) Kaplan–Meyer comparing prognosis in terms of Overall Survival (OS) for two groups of patients, those with high (mRNA expression  $> 1.2$  S.D.,  $n = 57$ ) and low (mRNA expression  $< 1.2$  S.D.,  $n = 491$ ) expression levels of MAPK11 for IR-treated invasive breast cancer patients from TCGA dataset. Statistical significance of the difference was evaluated by logrank test.

miR-155 [78]. In sum, all this evidence supports that abrogation of MAPK11 promotes radiosensitivity. However, the molecular mechanisms and timeframe by which MAPK11 induces senescence in response to IR needs to be further studied.

Finally, our observations could be relevant for the design of clinical trials in which p38MAPK inhibitors are combined with radiotherapy, as in the case of glioblastoma [79]. The use of genetic approaches is an excellent proof of concept, yet their clinical implementation presents obvious difficulties relative to the use of pharmacological inhibitors. Hence, the search for specific molecules able to modulate MAPK11 (e.g. PROTAC technology [80]) is an interesting possibility that should be considered as a future research avenue. In addition, MAPK11 potential as a biomarker in response to IR would be worth exploring, especially in those tumors in which MAPK11 has been implicated and radiotherapy is a cornerstone of the treatment (e.g. female cancers or lung cancer [81,82]).

In sum, our proof-of-concept results indicate that MAPK11 is a key player in the cellular response to IR through the control of senescence. However, further research is necessary to fully exploit the potential of this MAPK as a target for radiosensitization and/or as a predictive marker for the efficacy of radiotherapy.

#### Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

#### Acknowledgments

We would like to thank the staff from the Radiotherapy Unit at the Hospital General Universitario de Albacete for technical support. We

also appreciate the technical assistance of SIB at CRIB and core facilities of IIB: We also appreciate the support of Taller Solidario Árbol De La Vida (Las Pedroñeras), Asociación Comarcal Contra El Cáncer De Motilla Del Palancar and ACEPAIN in our research.

#### Funding

This work has been supported with Grant PID2021-122222OB-I00 funded by MCIN/AEI/10.13039/501100011033, “ERDF A way of making Europe” to RSP. Also supported with funds from Fundación Leticia Castillejo Castillo (2021-AYUDA-32401) to RSP and MJRH and grant. 2022-GRIN-34150 (UCLM) to RSP. RSP and MJRH’s Research Institute and the work carried out in their laboratory, received partial support from the European Community through the FEDER. This work was also supported by a EMBO Short-Term Fellowship to DMFA. JJ holds a predoctoral research contract co-funded by the European Social Fund and UCLM. DV holds a personal Fellowship from the BHF (FS/18/39/33684). ARG and SF are supported by grants from Barts Charity and the BHF (MGU0501 and FS/18/39/33684 to DV). NGF has been supported by the Investigo Programme, within the framework of the Recovery, Transformation and Resilience Plan - funded by the European Union - Next Generation EU -, called by Order 190/2021, of 22 December, of the Regional Ministry of Economy, Business and Employment of the Regional Government of Castilla-La Mancha. FJC is funded by contracts for post-doctoral researchers for scientific excellence in the development of the Plan Propio I + D + i, co-funded by the European Social Fund Plus (ESF+).

#### Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ctro.2023.100649>.

## References

- [1] Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. *Cancer* 2005;104:1129–37. <https://doi.org/10.1002/cncr.21324>.
- [2] NHS. National Cancer Registration and Analysis Service n.d. <https://www.cancerdata.nhs.uk/> (accessed July 18, 2022).
- [3] Zhu X, Wang Y, Jiang C, Li X, Sun L, Wang G, et al. Radiosensitivity-Specific Proteomic and Signaling Pathway Network of Non-Small Cell Lung Cancer (NSCLC). *Int J Radiat Oncol Biol Phys* 2022;112(2):529–41.
- [4] El-Nachef L, Al-Chobq J, Restier-Verlet J, Granzotto A, Berthel E, Sonzogni L, et al. Human Radiosensitivity and Radiosusceptibility: What Are the Differences? *Int J Mol Sci* 2021;22(13):7158.
- [5] de Mey S, Dufait I, De Ridder M. Radioresistance of Human Cancers: Clinical Implications of Genetic Expression Signatures. *Frontiers in Oncology*. 2021. 11.
- [6] Fowler JF. Chemical modifiers of radiosensitivity-theory and reality: A review. *Int J Radiat Oncol Biol Phys* 1985;11:665–74. [https://doi.org/10.1016/0360-3016\(85\)90296-2](https://doi.org/10.1016/0360-3016(85)90296-2).
- [7] Park HS, You GE, Yang KH, Kim JY, An S, Song J-Y, et al. Role of AKT and ERK pathways in controlling sensitivity to ionizing radiation and adaptive response induced by low-dose radiation in human immune cells. *Eur J Cell Biol* 2015;94(12):653–60.
- [8] Zhou S, Zhang M, Zhou C, Wang W, Yang H, Ye W. The role of epithelial-mesenchymal transition in regulating radioresistance. *Crit Rev Oncol Hematol* 2020;150:102961. <https://doi.org/10.1016/j.critrevonc.2020.102961>.
- [9] Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. *Int J Radiat Oncol Biol Phys* 2004;59:928–42. <https://doi.org/10.1016/j.ijrobp.2004.03.005>.
- [10] Vallard A, Bernichon E, Wang Q, Attignon V, Pissaloux D, Bachelot T, et al. Genomic Alterations and Radioresistance in Breast Cancer: An Analysis of the Profiler Protocol. *Int J Radiat Oncol Biol Phys* 2017;99(2):S52.
- [11] Rowinski E, Magné N, Fayette J, Daguinet E, Racadot S, Pommier P, et al. Radioresistance and genomic alterations in head and neck squamous cell cancer: Sub-analysis of the Profiler protocol. *Head Neck* 2021;43:3899–910. <https://doi.org/10.1002/hed.26891>.
- [12] Belli M, Tabocchini MA. Ionizing Radiation-Induced Epigenetic Modifications and Their Relevance to Radiation Protection. *Int J Mol Sci* 2020;21:5993. <https://doi.org/10.3390/ijms21175993>.
- [13] Cuenda A, Rousseau S. p38 MAP-Kinases pathway regulation, function and role in human diseases. *Biochimica et Biophysica Acta (BBA) - Molecular. Cell Res* 2007;1773(8):1358–75.
- [14] Korb A, Tohidast-Akrad M, Cetin E, Axmann R, Smolen J, Schett G. Differential tissue expression and activation of p38 MAPK alpha, beta, gamma, and delta isoforms in rheumatoid arthritis. *Arthritis Rheum* 2006;54:2745–56. <https://doi.org/10.1002/art.22080>.
- [15] Yang C, Cao P, Gao Y, Wu M, Lin Y, Tian Y, et al. Differential expression of p38 MAPK  $\alpha$ ,  $\beta$ ,  $\gamma$ ,  $\delta$  isoforms in nucleus pulposus modulates macrophage polarization in intervertebral disc degeneration. *Sci Rep* 2016;6:22182. <https://doi.org/10.1038/srep22182>.
- [16] Wang H, Xu Q, Xiao F, Jiang Y, Wu Z, Bronner-Fraser M. Involvement of the p38 Mitogen-activated Protein Kinase  $\alpha$ ,  $\beta$ , and  $\gamma$  Isoforms in Myogenic Differentiation. *MBoC* 2008;19(4):1519–28.
- [17] Qin J-Z, Xin H, Qi X-M, Chen G. Isoform-specific and cell/tissue-dependent effects of p38 MAPKs in regulating inflammation and inflammation-associated oncogenesis. *Frontiers in Bioscience-Landmark* 2022;27:31. <https://doi.org/10.31083/j.fbl2701031>.
- [18] García-Hernández L, García-Ortega MB, Ruiz-Alcalá G, Carrillo E, Marchal JA, García MÁ. The p38 MAPK Components and Modulators as Biomarkers and Molecular Targets in Cancer. *Int J Mol Sci* 2021;23:370. <https://doi.org/10.3390/ijms23010370>.
- [19] García-Cano J, Roche O, Cimas FJ, Pascual-Serra R, Ortega-Muelas M, Fernández-Aroca DM, et al. p38MAPK and Chemotherapy: We Always Need to Hear Both Sides of the Story. *Front Cell Dev Biol* 2016;4:69. <https://doi.org/10.3389/fcell.2016.00069>.
- [20] Pramanik R, Qi X, Borowicz S, Choubey D, Schultz RM, Han J, et al. p38 Isoforms Have Opposite Effects on AP-1-dependent Transcription through Regulation of c-Jun: THE DETERMINANT ROLE OF THE ISOFORMS IN THE p38 MAPK SIGNAL SPECIFICITY\*. *J Biol Chem* 2003;278(7):4831–9.
- [21] Tian XIAODONG, Traub BENNO, Xie XUEHAI, Zhou SHAOXIA, Hennebruns DORIS, Knippschild UWE, et al. Opposing Oncogenic Functions of p38 Mitogen-activated Protein Kinase Alpha and Beta in Human Pancreatic Cancer Cells. *Anticancer Res* 2020;40(10):5545–56.
- [22] Canovas B, Nebreda AR. Diversity and versatility of p38 kinase signalling in health and disease. *Nat Rev Mol Cell Biol* 2021;22:346–66. <https://doi.org/10.1038/s41580-020-00322-w>.
- [23] Del Reino P, Alsina-Beauchamp D, Escós A, Cerezo-Guisado MI, Risco A, Aparicio N, et al. Pro-oncogenic role of alternative p38 mitogen-activated protein kinases p38 $\gamma$  and p38 $\delta$ , linking inflammation and cancer in colitis-associated colon cancer. *Cancer Res* 2014;74:6150–60. doi: 10.1158/0008-5472.CAN-14-0870.
- [24] Fajardo P, Taskova M, Martín-Serrano MA, Hansen J, Slott S, Jakobsen AK, et al. p38 $\gamma$  and p38 $\delta$  as biomarkers in the interplay of colon cancer and inflammatory bowel diseases. *Cancer Commun (Lond)* 2022;42(9):897–901.
- [25] Roche O, Fernández-Aroca DM, Arconada-Luque E, García-Flores N, Mellor LF, Ruiz-Hidalgo MJ, et al. p38 $\beta$  and Cancer: The Beginning of the Road. *Int J Mol Sci* 2020;21(20):7524.
- [26] Raman M, Earnest S, Zhang K, Zhao Y, Cobb MH. TAO kinases mediate activation of p38 in response to DNA damage. *EMBO J* 2007;26:2005–14. <https://doi.org/10.1038/sj.emboj.7601668>.
- [27] Im J-S, Lee J-K. ATR-dependent Activation of p38 MAP Kinase Is Responsible for Apoptotic Cell Death in Cells Depleted of Cdc7\*. *J Biol Chem* 2008;283:25171–7. <https://doi.org/10.1074/jbc.M802851200>.
- [28] Choi S-Y, Kim M-J, Kang C-M, Bae S, Cho C-K, Soh J-W, et al. Activation of Bak and Bax through c-Abl-Protein Kinase C $\delta$ -p38 MAPK Signaling in Response to Ionizing Radiation in Human Non-small Cell Lung Cancer Cells\*. *J Biol Chem* 2006;281(11):7049–59.
- [29] Kim M-J, Byun J-Y, Yun C-H, Park I-C, Lee K-H, Lee S-J. c-Src-p38 mitogen-activated protein kinase signaling is required for Akt activation in response to ionizing radiation. *Mol Cancer Res* 2008;6:1872–80. doi: 10.1158/1541-7786.MCR-08-0084.
- [30] Liang N, Zhong R, Hou X, Zhao G, Ma S, Cheng G, et al. Ataxia-telangiectasia mutated (ATM) participates in the regulation of ionizing radiation-induced cell death via MAPK14 in lung cancer H1299 cells. *Cell Prolif* 2015;48(5):561–72.
- [31] Lafarga V, Cuadrado A, Lopez de Silanes I, Bengochea R, Fernandez-Capetillo O, Nebreda AR. p38 Mitogen-activated protein kinase- and HuR-dependent stabilization of p21(Cip1) mRNA mediates the G(1)/S checkpoint. *Mol Cell Biol* 2009;29:4341–51. <https://doi.org/10.1128/MCB.00210-09>.
- [32] Wang X, McGowan CH, Zhao M, He L, Downey JS, Fearn C, et al. Involvement of the MKK6-p38 $\gamma$  Cascade in  $\gamma$ -Radiation-Induced Cell Cycle Arrest. *Mol Cell Biol* 2000;20(13):4543–52.
- [33] Pascual-Serra R, Fernández-Aroca DM, Sabater S, Roche O, Andrés I, Ortega-Muelas M, et al. p38 $\beta$  (MAPK11) mediates gemcitabine-associated radioresistance in sarcoma experimental models. *Radiother Oncol* 2021;156:136–44.
- [34] Ren F, Li B, Wang C, Wang Y, Cui B. Iodine-125 seed represses the growth and facilitates the apoptosis of colorectal cancer cells by suppressing the methylation of miR-615 promoter. *BMC Cancer* 2022;22:49. <https://doi.org/10.1186/s12885-021-09141-4>.
- [35] Chen Y-T, Tseng T-T, Tsai H-P, Kuo S-H, Huang M-Y, Wang J-Y, et al. Serine protease inhibitor Kazal type 1 (SPINK1) promotes proliferation, migration, invasion and radiation resistance in rectal cancer patients receiving concurrent chemoradiotherapy: a potential target for precision medicine. *Hum Cell* 2022;35(6):1912–27.
- [36] Ding W, Lu Y, Zhou A, Chen Y, Wang Z, Wang L, et al. Mast1 mediates radiation-induced gastric injury via the P38 MAPK pathway. *Exp Cell Res* 2021;409(2):112913.
- [37] Song Y-H, Chai Q, Wang N, Yang F-F, Wang G-H, Hu J-Y. X-rays induced IL-8 production in lung cancer cells via p38/MAPK and NF- $\kappa$ B pathway. *Int J Radiat Biol* 2020;96:1374–81. <https://doi.org/10.1080/09553002.2020.1683643>.
- [38] Wang K, Tang J, Liu X, Wang Y, Chen W, Zheng R. UBR5 regulates proliferation and radioresistance in human laryngeal carcinoma via the p38/MAPK signaling pathway. *Oncol Rep* 2020;44:685–97. <https://doi.org/10.3892/or.2020.7620>.
- [39] Xu M-D, Liu S-L, Zheng B-B, Wu J, Wu M-Y, Zhang Y, et al. The radiotherapy-sensitization effect of cantharidin: Mechanisms involving cell cycle regulation, enhanced DNA damage, and inhibited DNA damage repair. *Pancreatol* 2018;18(7):822–32.
- [40] Camero S, Vitali G, Pontecorvi P, Ceccarelli S, Anastasiadou E, Cicchetti F, et al. DNMT3A and DNMT3B Targeting as an Effective Radiosensitizing Strategy in Embryonal Rhabdomyosarcoma. *Cells* 2021;10(11):2956.
- [41] Hur J-M, Yun H-J, Yang S-H, Lee W-Y, Joe M-H, Kim D. Gliotoxin enhances radiotherapy via inhibition of radiation-induced GADD45a, p38, and NFKappaB activation. *J Cell Biochem* 2008;104:2174–84. <https://doi.org/10.1002/jcb.21776>.
- [42] Viktorsson K, Ekedahl J, Lindebro MC, Lewensohn R, Zhivotovskiy B, Linder S, et al. Defective stress kinase and Bak activation in response to ionizing radiation but not cisplatin in a non-small cell lung carcinoma cell line. *Exp Cell Res* 2003;289(2):256–64.
- [43] Fernández-Aroca DM, Roche O, Sabater S, Pascual-Serra R, Ortega-Muelas M, Sánchez Pérez I, et al. P53 pathway is a major determinant in the radiosensitizing effect of Palbociclib: Implication in cancer therapy. *Cancer Lett* 2019;451:23–33.
- [44] Fulco CP, Munschauer M, Anyoha R, Munson G, Grossman SR, Perez EM, et al. Systematic mapping of functional enhancer-promoter connections with CRISPR interference. *Science* 2016;354(6313):769–73.
- [45] Gilbert L, Horlbeck M, Adamson B, Villalta J, Chen Y, Whitehead E, et al. Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. *Cell* 2014;159(3):647–61.
- [46] Serrano-Oviedo L, Ortega-Muelas M, García-Cano J, Valero ML, Cimas FJ, Pascual-Serra R, et al. Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion. *PLoS One* 2018;13(7):e0200878.
- [47] Cimas FJ, Callejas-Valera JL, García-Olmo DC, Hernández-Losa J, Melgar-Rojas P, Ruiz-Hidalgo MJ, et al. E1a is an exogenous in vivo tumour suppressor. *Cancer Lett* 2017;399:74–81.
- [48] Mandegar M, Huebsch N, Frolov E, Shin E, Truong A, Olvera M, et al. CRISPR Interference Efficiently Induces Specific and Reversible Gene Silencing in Human iPSCs. *Cell Stem Cell* 2016;18(4):541–53.
- [49] Labun K, Montague TG, Krause M, Torres Cleuren YN, Tjeldnes H, Valen E. CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing. *W174 Nucleic Acids Res* 2019;47:W171. <https://doi.org/10.1093/nar/gkz365>.
- [50] Stojic L. Tuning the Expression of Long Noncoding RNA Loci with CRISPR Interference. *Methods Mol Biol* 2020;2161:1–16. [https://doi.org/10.1007/978-1-0716-0680-3\\_1](https://doi.org/10.1007/978-1-0716-0680-3_1).



- [51] Valero ML, Cimas FJ, Arias L, Melgar-Rojas P, García E, Callejas-Valera JL, et al. El1 promotes c-Myc-dependent replicative stress: implications in glioblastoma radiosensitization. *Cell Cycle* 2014;13(1):52–61.
- [52] González JE, Lee M, Barquinero JF, Valente M, Roch-Lefèvre S, García O. Quantitative image analysis of gamma-H2AX foci induced by ionizing radiation applying open source programs. *Anal Quant Cytol Histol* 2012;34:66–71.
- [53] de la Cruz-Morcillo MA, García-Cano J, Arias-González L, García-Gil E, Artacho-Cordón F, Ríos-Arrabal S, et al. Abrogation of the p38 MAPK  $\alpha$  signaling pathway does not promote radioresistance but its activity is required for 5-Fluorouracil-associated radiosensitivity. *Cancer Lett* 2013;335(1):66–74.
- [54] Franken NAP, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. *Nat Protoc* 2006;1:2315–9. <https://doi.org/10.1038/nprot.2006.339>.
- [55] van Leeuwen CM, Oei AL, Crezee J, Bel A, Franken NAP, Stalpers LJA, et al. The alpha and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. *Radiat Oncol* 2018;13(1). <https://doi.org/10.1186/s13014-018-1040-z>.
- [56] Adrados I, Larrasa-Alonso J, Galarreta A, López-Antona I, Menéndez C, Abad M, et al. The homeoprotein SIX1 controls cellular senescence through the regulation of p16INK4A and differentiation-related genes. *Oncogene* 2016;35(27):3485–94.
- [57] Olive PL, Banáth JP. The comet assay: a method to measure DNA damage in individual cells. *Nat Protoc* 2006;1:23–9. <https://doi.org/10.1038/nprot.2006.5>.
- [58] Gyori BM, Venkatachalam G, Thiagarajan PS, Hsu D, Clement M-V. OpenComet: An automated tool for comet assay image analysis. *Redox Biol* 2014;2:457–65. <https://doi.org/10.1016/j.redox.2013.12.020>.
- [59] Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. *Sci Signal* 2013;6(269). <https://doi.org/10.1126/scisignal.2004088>.
- [60] Luo H, Yount C, Lang H, Yang A, Riemer EC, Lyons K, et al. Activation of p53 with Nutlin-3a radiosensitizes lung cancer cells via enhancing radiation-induced premature senescence. *Lung Cancer* 2013;81(2):167–73.
- [61] López-Antona I, Contreras-Jurado C, Luque-Martín L, Carpintero-Leyva A, González-Méndez P, Palmero I. Dynamic regulation of myofibroblast phenotype in cellular senescence. *Aging Cell* 2022;21:e13580.
- [62] Little JB. *Principal Cellular and Tissue Effects of Radiation*. Holland-Frei Cancer Medicine 6th Edition 2003.
- [63] Wang Y, Liu L, Zhou D. Inhibition of p38 MAPK attenuates ionizing radiation-induced hematopoietic cell senescence and residual bone marrow injury. *Radiat Res* 2011;176:743–52. <https://doi.org/10.1667/rr2727.1>.
- [64] Hong E-H, Lee S-J, Kim J-S, Lee K-H, Um H-D, Kim J-H, et al. Ionizing Radiation Induces Cellular Senescence of Articular Chondrocytes via Negative Regulation of SIRT1 by p38 Kinase\*. *J Biol Chem* 2010;285(2):1283–95.
- [65] Zdanov S, Debacq-Chainiaux F, Remacle J, Toussaint O. Identification of p38MAPK-dependent genes with changed transcript abundance in H2O2-induced premature senescence of IMR-90 hTERT human fibroblasts. *FEBS Lett* 2006;580: 6455–63. <https://doi.org/10.1016/j.febslet.2006.10.064>.
- [66] Ståhl S, Kaminsky VO, Efazat G, Hyrslova Vaculova A, Rodriguez-Nieto S, Moshfegh A, et al. Inhibition of Ephrin B3-mediated survival signaling contributes to increased cell death response of non-small cell lung carcinoma cells after combined treatment with ionizing radiation and PKC 412. *Cell Death Dis* 2013;4: e454. doi: 10.1038/cddis.2012.188.
- [67] Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. *FEBS Lett* 1995;364:229–33. [https://doi.org/10.1016/0014-5793\(95\)00357-f](https://doi.org/10.1016/0014-5793(95)00357-f).
- [68] Shin J-H, Jeong J-Y, Jin Y, Kim I-D, Lee J-K. p38 $\beta$  MAPK affords cytoprotection against oxidative stress-induced astrocyte apoptosis via induction of  $\alpha$ B-crystallin and its anti-apoptotic function. *Neurosci Lett* 2011;501:132–7. <https://doi.org/10.1016/j.neulet.2011.06.061>.
- [69] McClung JM, Judge AR, Powers SK, Yan Z. p38 MAPK links oxidative stress to autophagy-related gene expression in cachectic muscle wasting. *C549 Am J Physiol Cell Physiol* 2010;298:C542. <https://doi.org/10.1152/ajpcell.00192.2009>.
- [70] Kim JK, Pedram A, Razandi M, Levin ER. Estrogen prevents cardiomyocyte apoptosis through inhibition of reactive oxygen species and differential regulation of p38 kinase isoforms. *J Biol Chem* 2006;281:6760–7. <https://doi.org/10.1074/jbc.M511024200>.
- [71] Liu Y, Wang G, Jiang X, Li W, Zhai C, Shang F, et al. TRIM67 inhibits tumor proliferation and metastasis by mediating MAPK11 in Colorectal Cancer. *J Cancer* 2020;11(20):6025–37.
- [72] Li Y, Kong C, Wu C, Wang Y, Xu B, Liang S, et al. Knocking down of LINC01220 inhibits proliferation and induces apoptosis of endometrial carcinoma through silencing MAPK11. *Biosci Rep* 2019;39:BSR20181794. doi: 10.1042/BSR20181794.
- [73] Eichner LJ, Curtis SD, Brun SN, Baumgart JT, Ross DS, Rymoff TJ, et al. HDAC3 regulates senescence and lineage specificity in non-small cell lung cancer 2021: 2020.10.14.338590. doi: 10.1101/2020.10.14.338590.
- [74] Mahlknecht U, Will J, Varin A, Hoelzer D, Herbein G. Histone Deacetylase 3, a Class I Histone Deacetylase, Suppresses MAPK11-Mediated Activating Transcription Factor-2 Activation and Represses TNF Gene Expression. *The Journal of Immunology* 2004. 173. 3979–90. doi: 10.4049/jimmunol.173.6.3979.
- [75] Desai S, Kumar A, Laskar S, Pandey BN. Differential roles of ATF-2 in survival and DNA repair contributing to radioresistance induced by autocrine soluble factors in A549 lung cancer cells. *Cell Signal* 2014;26:2424–35. <https://doi.org/10.1016/j.cellsig.2014.07.021>.
- [76] Wang S, Zhu W, Ouyang L, Li J, Li S, Yang X. Up-Regulation of Tiam1 Promotes the Radioresistance of Laryngeal Squamous Cell Carcinoma Through Activation of the JNK/ATF-2 Signaling Pathway. *Oncotargets Ther* 2020;13:7065–74. <https://doi.org/10.2147/OTT.S257748>.
- [77] Ronai Z, Yang YM, Fuchs SY, Adler V, Sardana M, Herlyn M. ATF2 confers radiation resistance to human melanoma cells. *Oncogene* 1998;16:523–31. <https://doi.org/10.1038/sj.onc.1201566>.
- [78] Wang Y, Scheiber MN, Neumann C, Calin GA, Zhou D. MicroRNA regulation of ionizing radiation-induced premature senescence. *Int J Radiat Oncol Biol Phys* 2011;81:839–48. <https://doi.org/10.1016/j.ijrobp.2010.09.048>.
- [79] Biau J, Thivat E, Chautard E, Stefan D, Boone M, Chaffert B, et al. Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma. *Radiother Oncol* 2021;154:227–34.
- [80] Donoghue C, Cubillos-Rojas M, Gutierrez-Prat N, Sanchez-Zarzalejo C, Verdaguer X, Riera A, et al. Optimal linker length for small molecule PROTACs that selectively target p38 $\alpha$  and p38 $\beta$  for degradation. *Eur J Med Chem* 2020;201: 112451.
- [81] Katopodis P, Kerslake R, Zikopoulos A, Beri N, Anikin V. p38 $\beta$  - MAPK11 and its role in female cancers. *Journal of Ovarian Research* 2021;14:84. <https://doi.org/10.1186/s13048-021-00834-9>.
- [82] Sullivan I, Riera P, Andrés M, Altés A, Majem M, Blanco R, et al. Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients. *Angiogenesis* 2019;22(3):433–40.